Biologics formulation: learn how Boehringer Ingelheim uses Prometheus to find optimal buffer conditions for their mAbs

November 9, 2018

Learn how the Global Formulation Development group at Boehringer Ingelheim uses thermal (conformational) stability information in tandem with aggregation (colloidal stability) monitoring to find ideal buffer conditions for their mAbs. 

You’ll learn about:

  • Why formulation optimization is critical for long-term stability of therapeutic mAbs
  • How Boehringer Ingelheim approaches stability studies for their formulation work
  • Why applying a combinatorial assessment of multiply stability aspects is critical for a deeper understanding of the impact of buffer formulation on stability 

Why it’s important to early discovery protein scientists:
The chemical environment of a protein-based therapeutic, such as a mAb, has a profound impact on whether or not a candidate remains stable long-term for downstream assays, storage, and administration. Formulation optimization is a critical step in optimizing your biologics for further use, but presents challenges in throughput and efficiency, as researchers must screen many buffer formulations. With Prometheus, it is possible to get conformational and colloidal stability information from a single experiment, which offers deeper insight into the impact a formulation has on the viability of your candidates.

Want to know about high precision tools for the combined characterization of thermal and colloidal stability of biologics? Learn more about Prometheus Panta

Previous Article
Predicting antibody developability profiles through early stage discovery screening
Predicting antibody developability profiles through early stage discovery screening

Up next
How stability studies get your mAb candidate FDA-approved
How stability studies get your mAb candidate FDA-approved

Want to see more
biologics content?

Explore resources